Antisense Therapeutics Limited (AU:PER) has released an update.
Percheron Therapeutics Limited, a biotech firm specializing in rare disease therapies, has updated its corporate presentation, detailing recent advancements and future goals. The presentation, which replaces the one from February, will be used in upcoming investor discussions and at several investor conferences in September 2024. Their lead drug, ATL1102, is currently in an international phase IIb trial for Duchenne Muscular Dystrophy, with results expected in the second half of 2024.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
